Aura Biosciences, Inc.
AURA Nasdaq
SEC CIK 1501796
Follow Aura Biosciences
Weekly email: filings, results
Net income
−$32.1M
−22.7% vs same quarter last year
EPS, diluted
−$0.29
+27.5% vs same quarter last year
Operating cash flow
−$26.4M
−31.3% vs same quarter last year
Operating income
−$35.1M
−25.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$106.2M |
| FY24 | −$86.9M |
| FY23 | −$76.4M |
| FY22 | −$58.8M |
| FY21 | −$35.3M |
| FY20 | −$22.2M |
| FY19 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$85.2M |
| FY24 | −$81.1M |
| FY23 | −$64.6M |
| FY22 | −$55.7M |
| FY21 | −$34.5M |
| FY20 | −$25.1M |
| FY19 | - |